Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL
Highlights
This phase 1, open-label, single-arm study evaluated ThisCAR-T, a non-gene-edited, CD19-targeted allogeneic CAR-T cell product, in 11 patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Among 9 patients evaluable at day 28, 8 achieved complete remission or complete remission with incomplete hematologic recovery, suggesting meaningful early antileukemic activity.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.